by: Parent Project Muscular Dystrophy
Sarepta Therapeutics, Inc. recently joined Parent Project Muscular Dystrophy (PPMD) for a community webinar update to discuss PPMO, Sarepta’s next generation precision RNA-targeting therapeutic platform for use in Duchenne muscular dystrophy.
During the webinar, Sarepta also introduced their planned innovative enhancements to the trial design for their actively enrolling Phase 1 clinical trial, 5051-101, for their PPMO exon 51 candidate (SRP-5051, NCT: 03375255), and outline their plans for future development of additional exon targets.
